Ketamine by Mail: What the Evidence Supports — and What the At-Home Boom Assumed

Ketamine is the rare psychedelic-adjacent treatment that never had to wait for a regulatory breakthrough. The clinic version — intravenous infusions in physician practices, and the FDA-approved esketamine nasal spray Spravato in certified settings — rests on randomized trials. The version most people encounter first today is different: telehealth platforms that ship compounded ketamine lozenges or tablets to a patient’s home, paired with video check-ins and, in some programs, daily low dosing. Companies in this market advertise six-session programs for around $1,290, daily microdosing subscriptions from about $129 a month, and monthly lozenge plans near $399. It is the fastest-growing segment of the psychedelic medicine economy, and it runs on an evidence base that is real, encouraging, and not actually about the product being sold.

What holds up

The rapid antidepressant effect of ketamine given in supervised settings is one of the better-supported findings in modern psychiatry. In TRANSFORM-2, the pivotal trial behind Spravato’s 2019 approval, 227 adults with treatment-resistant depression were randomized to flexibly dosed esketamine nasal spray or placebo spray, each added to a newly started oral antidepressant; at day 28 the esketamine group scored 4.0 points better on the MADRS depression scale, a modest but statistically significant between-group difference. The Cochrane review of ketamine and related glutamate-modulating drugs, updated in 2021 across 64 randomized studies and 5,299 participants, found short-term antidepressant benefit with the usual caveats — small trials, blinding difficulties, limited follow-up.

The supervision matters as much as the molecule. Spravato is dispensed under a risk-management program that requires the dose to be administered in a certified healthcare setting, observed, with at least two hours of monitoring including blood-pressure checks and respiratory assessment, and no driving until the patient has rested and slept. The trials that generated the efficacy numbers were conducted inside that kind of apparatus.

What doesn’t hold up

The at-home product is a different thing in every respect that regulation and pharmacology care about. Compounded racemic ketamine taken as an oral lozenge or tablet has no FDA-approved psychiatric indication; oral ketamine is not esketamine; the doses, schedules and patient selection used by telehealth platforms were not the ones tested in the pivotal trials. Evidence from a clinic IV infusion or a monitored nasal spray cannot simply be transferred across a change of route, formulation, dosing rhythm and monitoring — that is not a technicality, it is the whole question.

The strongest published support for the at-home model comes from company-associated observational studies. A 2022 study in the Journal of Affective Disorders followed 1,247 people who completed a four-week remote sublingual ketamine program and reported that 62.8 percent improved by at least 50 percent on the PHQ-9 depression scale, with 32.6 percent in remission. A 2024 follow-up analysis of 11,441 real-world patients reported adverse events in roughly 3 to 4.8 percent, predominantly psychiatric. Both are large, both are interesting, and both carry the same structural limits: no control group, self-reported scales, completer-based samples, four-week windows, and authors affiliated with the platform being studied. Expectation, natural recovery, and the other components of a supported program can all inflate an uncontrolled response rate.

The FDA reached the same conclusion from the safety side. On October 10, 2023, the agency warned patients and clinicians specifically about compounded ketamine — including oral formulations — taken for psychiatric disorders at home without monitoring, citing risks of sedation, dissociation, confusion, blood-pressure increases, misuse and abuse. The agency had earlier received a report of respiratory depression after compounded oral ketamine taken outside a healthcare setting, at a reported concentration roughly twice a level typically seen in anesthesia. That is one spontaneous case, not a rate — but it is the kind of event the at-home model has no apparatus to catch.

A lower price per session is not a lower threshold of evidence.

The regulatory picture has been wobbling along underneath the industry the entire time. The Ryan Haight Act of 2008 generally requires an in-person evaluation before a clinician prescribes controlled substances over the internet; the COVID-era public health emergency suspended that requirement for qualifying care. The DEA’s attempts to write a permanent rule — a proposed 30-day limit in February 2023, a proposed “special registration” framework in January 2025 — have each drawn hundreds of thousands of public comments and produced extensions instead. The currently operative one, published December 31, 2025, preserves qualifying telemedicine prescribing of Schedule III ketamine through December 31, 2026, with no permanent rule yet in place. An entire industry’s distribution model currently rests on a temporary federal extension.

The safety ledger has real entries on it. Chronic frequent ketamine exposure is associated with lower urinary tract and bladder toxicity — a concern that weighs more heavily on daily microdosing schedules than on the weekly-session protocols the clinic data describes. A take-home Schedule III drug creates storage, diversion and misuse questions that clinic-held dosing does not. A wrongful-death complaint filed in North Carolina in October 2025 against one major platform, alleging a 27-year-old patient died of ketamine toxicity in 2023 in the context of uncontrolled hypertension, is a documented allegation and not an adjudicated finding — and the platform’s observational studies, whatever their merits, cannot exclude rare catastrophic events that a supervised clinic would be positioned to intercept.

The cost math

The prices are genuinely different, and that difference is part of the appeal. In-clinic IV ketamine infusions typically run $600 to $1,000 per session, paid out of pocket — a six-treatment course can reach several thousand dollars. Spravato’s cost bundles drug and mandatory supervised monitoring, and insurance coverage varies. Against that, at-home programs are cheaper on almost every axis: roughly $215 per session in a six-session package, or $129 a month for daily microdosing. Those are different products with different schedules, not equivalent treatments at different prices — but for a patient paying cash, the comparison that determines behavior is the one the evidence base does not cover.

What a reader should take from this

Ketamine for depression is not fringe medicine; the supervised treatments have randomized evidence and one FDA-approved product, and the field’s enthusiasm is anchored in real data. But the at-home telehealth model — compounded tablets and lozenges, sometimes daily, at home, with a support person on video — has never been tested head-to-head against the clinic protocols the evidence was built in. The observational numbers are encouraging and uncontrolled; the FDA has warned about the model specifically; the DEA framework underneath it runs on temporary extensions.

Anyone considering the at-home route should ask three questions: whether they have been screened for uncontrolled hypertension, psychosis risk, and substance misuse; what happens if something goes wrong at home during a dissociative dose; and whether the daily microdosing schedule being offered has any randomized evidence at all — for the lowest-dose subscriptions, the honest answer is none. The cheaper option is not automatically the evidence-free one, but in this market the correlation runs strong enough to check before buying.

This article is general information, not medical advice. See our Editorial Standards.